文献速递糖尿病

在ACCORD-BP研究中符合SPRINT入选标准者的强化与标准血压控制对比

Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
PubMed 文献 · Diabetes Care · 2017-09-25

本研究为ACCORD-BP的事后亚组分析,纳入标准降糖组且符合SPRINT入选条件的2型糖尿病 participant,比较强化与标准血压控制对心血管结局的影响。强化组平均收缩压120 mmHg vs 标准组134 mmHg(P<0.001),强化血压控制降低复合心血管结局(HR 0.79;95%CI 0.65-0.96;P=0.02)及心血管死亡、非致死性心肌梗死和非致死性卒中(HR 0.69;95%CI 0.51-0.93;P=0.01),治疗相关不良事件更常见(4.1% vs 2.1%;P=0.003)。

要点

  • 强化血压控制降低2型糖尿病合并额外心血管风险者的复合心血管结局(HR 0.79;95%CI 0.65-0.96;P=0.02)。
  • 强化血压控制降低心血管死亡、非致死性心肌梗死和非致死性卒中(HR 0.69;95%CI 0.51-0.93;P=0.01)。
  • 治疗相关不良事件在强化血压控制组更频繁(4.1% vs 2.1%;P=0.003)。

核心结论

  • 在2型糖尿病合并额外心血管疾病风险因素的队列中,强化血压控制降低心血管结局。

研究设计与样本

  • ACCORD-BP研究的事后多变量亚组分析,纳入标准降糖组且符合SPRINT入选条件的参与者,并与SPRINT参与者合并分析。

主要发现

  • 强化与标准血压控制组平均基线Framingham 10年心血管疾病风险评分分别为14.5%和14.8%。
  • 强化与标准血压控制组平均达到的收缩压分别为120和134 mmHg(P<0.001)。
  • 强化血压控制降低心血管死亡、非致死性心肌梗死、非致死性卒中、任何血运重建和心力衰竭的复合结局(HR 0.79;95%CI 0.65-0.96;P=0.02)。
  • 强化血压控制降低心血管死亡、非致死性心肌梗死和非致死性卒中(HR 0.69;95%CI 0.51-0.93;P=0.01)。
  • 治疗相关不良事件在强化血压控制组更频繁(4.1% vs 2.1%;P=0.003)。

关键数值与推荐

  • 符合SPRINT入选条件定义为处于ACCORD-BP标准降糖组且具有SPRINT资格所需的额外心血管疾病风险因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS: This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM. RESULTS: The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (P < 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96; P = 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93; P = 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%; P = 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (P > 0.62). CONCLUSIONS: Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Buckley LF, Dixon DL, Wohlford GF, et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care. 2017. PMID: 28947569. doi:10.2337/dc17-1366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。